Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Constellation Energy is preparing to restart what's now called the Crane Clean Energy Center on Three Mile Island to supply ...
The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...
Logically Answered on MSN9d
Why 77,000 Cancer Patients Are Suing Pfizer (& Others)The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...
AI-enhanced manufacturing applications are now being deployed around the world as a massive upgrade in efficiency.
Haleon posted an unexpected drop in third-quarter revenue, hurt by a weak demand for its painkiller in Australia and the Middle East.
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback